Latest Ranolazine Stories
Editor Note: For more information about this release, please scroll to bottom. NEW YORK, May 20, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts'
A commonly used anti-anginal drug reduces chest pain in patients with type 2 diabetes and appears to have a more pronounced effect in those with poorer glucose control.
According to a study published in the journal JAMA, the use of beta-blockers was not associated with a lower risk of cardiovascular events.
New research finds ongoing treatment with ticagrelor safe and effective in patients with acute coronary syndrome.
Because of improved management at the acute stage, the risk of dying in hospital after a heart attack has decreased by about 50% in the past 10 years.
Although medication which decreases the risk of angina attacks (chest pain caused by blockage of the arteries that supply the heart), are frequently prescribed in patients who have sustained a myocardial infarction, the possible influence of medication on long-term survival is not known, with the exception of beta-blocking agents, which have been shown to decrease mortality in clinical trials performed 30 years ago.
New research published online today in Circulation Research found that injections of adult patients' own CD34+ stem cells reduced reports of angina episodes and improved exercise tolerance time in patients with chronic, severe refractory angina (severe chest discomfort that did not respond to other therapeutic options).
Ranolazine (Ranexa, Gilead) is an effective anti-anginal therapy in patients with refractory angina; however, at one year only 59 percent of patients remained on the drug.
PALO ALTO, Calif., March 12 /PRNewswire-FirstCall/ -- The Board of Directors of CV Therapeutics, Inc.
- Having no light.
- Of or relating to the region of a body of water that is not reached by sunlight and in which photosynthesis is unable to occur.